S. Seeber

Essen University Hospital — Germany

Medicine · Health Sciences

51h-index12.1kcitations442works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(61), Chronic Lymphocytic Leukemia Research(45), Cancer therapeutics and mechanisms(41), Testicular diseases and treatments(39), Lung Cancer Treatments and Mutations(37)

Publications440 total

Supplementary Figure Legends 1-3 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Table 2 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Table 2 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 1 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Table 1 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Data from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 1 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Data from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 2 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 2 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 3 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Table 1 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure 3 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Supplementary Figure Legends 1-3 from A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
2023Open Access
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
Journal of Cancer Research and Clinical Oncology·2020· 20 citedOpen Access
Results of Intracavitary Chemotherapy with Mitoxantrone
2015
Maligne Hodentumoren
2014
Maligne Hodentumoren
2014· 1 cited
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)
Lung Cancer·2013· 25 cited
Abstract 5420: Antitumor activity of nemorosone against pancreatic cancer cells and xenografts
Cancer Research·2011
page 1 of 22Next →

Frequent Co-authors

A. Harstrick(10), H. Wilke(9), Martin Stuschke(8), Dirk Strumberg(8), M. E. Scheulen(8), U. Vanhoefer(8), Michael Flaßhove(7), J. Schütte(7), Bertram Opalka(6), M. Stahl(5), Ralf A. Hilger(5), Wilfried Eberhardt(5), N. Niederle(5), Brian Schwartz(4), H. Sack(4), Peter R. Ebeling(4), Martin K. Walz(3), Heike Richly(3), N. Schleucher(3), E. Brendel(3)